Illumina (ILMN) : Tredje Ap-fonden scooped up 4,157 additional shares in Illumina during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 67,737 shares of Illumina which is valued at $9.3 Million.Illumina makes up approximately 0.43% of Tredje Ap-fonden’s portfolio.
Other Hedge Funds, Including , Ropes Wealth Advisors added ILMN to its portfolio by purchasing 500 company shares during the most recent quarter which is valued at $68,460. Illumina makes up approx 0.03% of Ropes Wealth Advisors’s portfolio.Schroder Investment Management Group reduced its stake in ILMN by selling 9,993 shares or 65.43% in the most recent quarter. The Hedge Fund company now holds 5,280 shares of ILMN which is valued at $722,938.Calvert Investment Management boosted its stake in ILMN in the latest quarter, The investment management firm added 1,128 additional shares and now holds a total of 8,265 shares of Illumina which is valued at $1.2 Million. Illumina makes up approx 0.05% of Calvert Investment Management’s portfolio.Mitsubishi Ufj Kokusai Asset Management Ltd. boosted its stake in ILMN in the latest quarter, The investment management firm added 2,084 additional shares and now holds a total of 22,028 shares of Illumina which is valued at $3.1 Million. Illumina makes up approx 0.08% of Mitsubishi Ufj Kokusai Asset Management Ltd.’s portfolio.Wedbush Securities Inc boosted its stake in ILMN in the latest quarter, The investment management firm added 1,009 additional shares and now holds a total of 15,701 shares of Illumina which is valued at $2.2 Million. Illumina makes up approx 0.39% of Wedbush Securities Inc’s portfolio.
Illumina opened for trading at $138.77 and hit $141.57 on the upside on Friday, eventually ending the session at $140.51, with a gain of 1.80% or 2.48 points. The heightened volatility saw the trading volume jump to 7,66,232 shares. Company has a market cap of $20,683 M.
On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.
Many Wall Street Analysts have commented on Illumina. Shares were Reiterated by Mizuho on May 4, 2016 to “Neutral” and Lowered the Price Target to $ 138 from a previous price target of $150 .Shares were Reiterated by Stifel on May 4, 2016 to “Buy” and Lowered the Price Target to $ 160 from a previous price target of $215 .Shares were Reiterated by Canaccord Genuity on May 4, 2016 to “Hold” and Lowered the Price Target to $ 140 from a previous price target of $160 .
Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.